Background: Metastatic gastric cancer has a poor prognosis. We aim to study how clinical features and prognosis differs between different metastatic sites, and to identify prognostic factors for overall survival.
INTRODUCTION
Gastric cancer continues to be a significant contributor to cancerrelated mortality across the world, accounting for 723,000 deaths per year, the third most frequent cause of cancer-related deaths. 1 There is a high prevalence of advanced disease at presentation, with up to 39-44% of newly diagnosed gastric cancer cases harboring disseminated disease at initial diagnosis. 2, 3 It has been well established that untreated metastatic gastric cancer carries a poor prognosis with a median overall survival of 4 months and 5-year survival rates of 3-6%. [4] [5] [6] Palliative systemic chemotherapy improves overall survival to a median of 7.5-12.3 months. [7] [8] [9] [10] In pushing the frontiers of managing patients with metastatic disease to achieve further improvements in long-term survival, we have seen notable results best characterized by colorectal cancer.
Colorectal cancer patients with limited metastatic disease isolated to a single site amenable to surgical resection have been shown to benefit from a multimodality approach encompassing systemic chemotherapy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. [11] [12] [13] [14] [15] [16] [17] In the field of metastatic gastric cancer, prospective series examining patients with isolated peritoneal metastasis have demonstrated efficacy of similar multimodality treatment approaches, yielding median overall survival in the range of 14.4-24.6 months. [18] [19] [20] [21] [22] [23] [24] [25] In addition, in the case of gastric cancer with positive peritoneal cytology but without overt peritoneal metastases (CY+P0), extensive intraoperative peritoneal lavage (EIPL) has been studied with promising results. 26 Apart from offering the possibility of prolonged survival, these modalities may offer palliation from peritoneal metastases that we postulate would result in significant symptoms if treated with systemic chemotherapy or best supportive care alone. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] As such, we aim to study the differences in clinical characteristics of different sites of gastric adenocarcinoma metastasis. In addition, we aim to examine if the site of metastasis affects overall survival in metastatic gastric adenocarcinoma patients is associated with tolerability of planned systemic chemotherapy, as well as to identify other potential prognostic factors so as to aid identification of subgroup(s) of patients who may eventually benefit from investigational multimodality treatment options.
METHODOLOGY
We performed a retrospective electronic chart review of a prospectively maintained database of all patients with metastatic gastric adenocarcinoma managed at the National Cancer Centre Singapore, the largest tertiary referral center for cancer treatment locally, over a 5-year period between January 2010 and December 2014. This study has been approved by the institutional ethics review board.
All patients included in our study had baseline radiological staging investigations performed following the initial diagnosis of gastric adenocarcinoma. These include computed tomography scans of the thorax, abdomen and pelvis to assess for distant metastases.
Patients without radiological evidence of metastatic disease subsequently underwent staging laparoscopy to assess for peritoneal metastases, with intraoperative frozen section histological confirmation where indicated.
Palliative systemic chemotherapy was offered as the standard of care in our institution to all patients with metastatic gastric adenocarcinoma. For each patient eventually planned for chemotherapy, the first-line chemotherapy regime was chosen based on the National Comprehensive Cancer Network Guidelines for Gastric Cancer Treatment. 28 The choice was further augmented based on each patient's performance status, medical co-morbidities and personal preferences, favoring two-to three-agent chemotherapy combinations over single-agent chemotherapy where possible. Trastuzumab was additionally offered in cases that were positive for Her2/Neu overexpression. Chemotherapy regime was switched or discontinued based on clinician discretion during the course of follow-up if patients experienced unacceptable levels of toxicity or had clinical evidence of disease progression. Chemotherapy was also put on hold or stopped entirely in the event of acute deteriorations in patients' functional and/or medical conditions. Other therapeutic interventions including surgery, endoscopic therapy and radiotherapy were also undertaken where clinically indicated.
We divided our cohort into three metastatic groups based on the site(s) of metastasis at initial presentation-peritoneal metastasis only (P), distant metastasis only (D) and peritoneal and distant metastases (PD).
Statistical analysis was performed using SPSS Statistics Version 19.0 (IBM Corp., Armonk, NY, USA). Continuous and categorical variables were analyzed using the one-way analysis of variance (ANOVA) test and chi-square test, whereas survival data and HRs were analyzed using Kaplan-Meier and Cox regression analyses, respectively. A statistical significance level of 5% was used.
RESULTS
We studied a total of 470 patients with an average age of 64.8 ± 13.4 years at initial diagnosis of metastatic gastric adenocarcinoma. There was a slight male preponderance (n = 264, 56.2%) and a predominant Chinese ethnicity (n = 372, 79.1%) in our cohort. We had 175 (37.2%), 193 (41.1%) and 102 (21.7%) patients in the P, D and PD metastatic groups, respectively. Of the 277 patients with peritoneal metastasis in the P and PD groups, peritoneal involvement was diagnosed through preoperative staging scans in 143 (51.6%) cases, and through diagnostic laparoscopy in the remaining 134 (48.4%) cases.
Comparison of clinical characteristics by metastatic groups
The baseline characteristics of these three groups of patients are presented in Table 1 . Of note, patients in D metastatic group were significantly older at presentation (average age 68.3 in D vs 62.4 in P vs 62.5 in PD, P < 0.001). Additionally, when comparing P to PD to D metastatic groups, there were increasing proportions of males (44.0% vs 55.9% vs 67.4%, P < 0.001) and cigarette smokers (16.6% vs 29.4% vs 30.1%, P = 0.006).
The gastric cancer and overall treatment characteristics of our three groups of patients are presented in Table 1 . Of note, patients in D metastatic group were more likely metastatic recurrences of previously treated gastric cancer and significantly associated with gastroesophageal junction tumors. However, patients in P metastatic group were associated with linitis plastica and a diffuse histology. Of our cohort of 470 patients, 274 (58.3%) were started on palliative systemic chemotherapy. A significantly lower proportion of patients in D metastatic group were started on palliative systemic chemotherapy as compared to the P and PD groups. In terms of other therapeutic interventions, P metastatic group had a significantly higher proportion of patients who underwent palliative gastrectomy, and a lower proportion of patients who received gastric stenting and palliative radiotherapy.
The palliative systemic chemotherapy treatment-related characteristics of the 274 patients started on chemotherapy across all three groups of patients are presented in Table 2 . All three groups had comparable first-line chemotherapy regimes, average total number of lines TA B L E 1 Comparison of baseline and general treatment characteristics of patients with peritoneal metastasis only (P), distant metastasis only (D) and both peritoneal and distant metastases (PD) of chemotherapy and average total number of chemotherapy cycles completed. Notably, patients with peritoneal disease (both P and PD groups) had significantly higher proportions of patients experiencing chemotherapy disruption due to unplanned hospitalizations. These disruptions were also of a significantly longer average duration compared to patients without peritoneal disease (P = 0.001).
The follow-up characteristics of our three groups of patients are presented in Table 3 . Although the incidence and average number of unplanned hospitalizations were comparable between all three groups, there were significant differences in the reasons for hospitalizations.
Patients with peritoneal disease had a higher proportion of hospitalizations for symptomatic ascites, intestinal obstruction and obstructive uropathy.
Comparison of overall survival by metastatic site
The overall median survival of our cohort was 6.9 months (95% CI, 6.0-7.8). Comparing between metastatic groups, patients in the P group had significantly (P < 0.001) the longest overall median survival of 8.9 months (95% CI, 7.7-10.2) as compared to the PD group with 7.4 months (95% CI, 5.8-8.9) and D group with 5.5 months (95% CI, 4.4-6.6). The survival curve of each metastatic group is shown in Figure 1 .
When we stratified the entire cohort of patients by initiation of palliative systemic chemotherapy, we found that there was no significant difference in overall survival between metastatic groups for patients who were initiated on chemotherapy (median overall survival of 10.2 months vs 11.7 months vs 9.7 months for P, PD and D groups,
F I G U R E 1 Overall survival of patients with peritoneal metastasis only (P), distant metastasis only (D) and both peritoneal and distant metastases (PD)
respectively; P = 0.312). However, among patients who were not initiated on chemotherapy, the P group still had significantly the longest median overall survival (median overall survival of 3.5 vs 2.3 vs 2.6 months for P, PD and D groups, respectively; P = 0.047).
In examining the subgroup of patients in our cohort with only one metastatic site (n = 280), we found that the specific site of isolated metastasis had varying associations with overall survival. Patients with peritoneal metastasis had lower overall mortality (HR 0.74; 95% CI, 0.56-0.98; P = 0.035), whereas patients with liver metastasis had higher overall mortality (HR 1.40; 95% CI, 1.01-1.95; P = 0.049). Isolated retroperitoneal lymph node metastasis (HR 1.03; 95% CI, 0.68-1.56; P = 0.887), bone metastasis (HR 1.09; 95% CI, 0.59-2.00; P = 0.792) and lung metastasis (HR 1.45; 95% CI, 0.54-3.91; P = 0.466) had no significant association with overall mortality.
Prognostic factors for overall survival
A subsequent Cox regression analysis undertaken to identify other potential prognostic factors for overall survival is presented in Table 4 .
Notably, following multivariate Cox regression analysis, the presence of ≥1 metastatic site (HR 1.67; 95% CI, 1.23-2.28; P = 0.001) was significantly associated with increased overall mortality, while palliative systemic chemotherapy (HR 0.29; 95% CI, 0.22-0.37; P < 0.001) and palliative gastrectomy (HR 0.24; 95% CI, 0.15-0.39; P < 0.001) were significantly associated with decreased overall mortality.
DISCUSSION
Metastatic gastric cancer has a notorious reputation for its high prevalence at initial diagnosis and poor prognosis even with the advent of palliative systemic chemotherapy. [2] [3] [4] [5] [6] [7] [8] [9] [10] Advancements in the management of metastatic intraabdominal malignancies seeking not just to palliate but to push boundaries on achieving significant improvements in overall survival have been contingent upon the identification of subgroups of each metastatic malignancy who may best benefit from targeted, multimodality therapeutic interventions. Examples include the application of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal, appendiceal mucinous neoplasms and ovarian metastases to the peritoneum, 11, 12, 29 and the use of metastasectomy in isolated colorectal and neuroendocrine metastases to the liver. [13] [14] [15] [16] [17] 30 With the growing interest in improving survival outcomes in patients with metastatic gastric cancer, it is hence imperative that we examine how the site(s) of metastasis and other clinical features affect the clinical course and overall survival of metastatic gastric cancer patients.
We found that gastric peritoneal metastasis is associated with a younger age, female gender, linitis plastica and a diffuse histology, consistent with several metastatic gastric cancer series in existing literature. 2, 31 However, distant metastases are more commonly seen in patients who smoke cigarettes and have proximal gastric adenocarcinoma (gastroesophageal or cardia primaries). The close association between smoking and proximal gastric cancers has been well documented in epidemiological studies examining gastric cancer risk factors. 32, 33 In terms of clinical course, for the entire cohort, whereas there was no significant difference in number of hospitalizations, the primary reason for hospitalization among patients with peritoneal metastasis was more frequently a peritoneal disease-related complication such as symptomatic ascites, intestinal obstruction and obstructive uropathy. Among the patients who were started on palliative systemic chemotherapy, peritoneal metastasis was associated with a significantly higher rate of chemotherapy disruption due to unplanned hospitalizations, which in turn were of a significantly longer duration. This has previously been reported to be a significant clinical hurdle in the treatment of gastric peritoneal carcinomatosis, 18, 27 prompting alternative treatment modalities aimed at overcoming the seemingly inevitable deteriorative effect peritoneal metastasis possesses.
Despite the more eventful clinical course of patients with peritoneal metastasis, we found that they had a consistently better overall survival as compared to patients with distant metastasis both when examining the entire cohort and the subgroup with only a single site of metastasis. However, we found that liver metastasis was associated with a poorer survival among patients with a single site of metastasis, consistent with several gastric cancer prognostic indices. 34, 35 This could in part be due to the hypothesis that peritoneal metastasis constitutes an extension of locoregional disease in gastric cancer arising from transcoelomic spread as opposed to solid organ metastases which constitute truly distant disease arising from hematogenous dissemination. 36 Interestingly, we found that among patients who were initiated on palliative systemic chemotherapy, the group of patients with peritoneal metastasis only no longer demonstrated a significantly better overall median survival when compared to the other metastatic On this front, in a bid to achieve further improvements in sur- and 1-year overall survival rates as high as 91%. [18] [19] [20] [21] [22] [23] [24] Recognizing that such treatment approaches come with their attendant morbidities, in an attempt to refine the selection of patients who may best benefit from aggressive locoregional therapies, another related investigational staged treatment approach, conversion surgery, is currently being explored. 25 This approach subjects patients to concomitant systemic and intraperitoneal chemotherapy upfront before selecting the subgroup with complete peritoneal metastatic remission to undergo subsequent "conversion gastrectomy," achieving median survival rates of 21.6 months in a small prospective series. 25 In addition, in the specific patient subgroup with CY+P0 metastatic disease, EIPL has been studied as a promising and effective strategy in improving long-term overall survival. 26 Through multivariate Cox regression analysis, our study identified three major independent prognostic factors for overall survival among patients with metastatic gastric cancer, namely ≥1 metastatic site, palliative systemic chemotherapy and palliative gastrectomy. The multiplicity of metastatic sites likely serves as a surrogate measure of the extent of metastatic progression of the primary gastric malignancy, which may account for its prognostic value as also reported by various gastric cancer prognostic indices. 34, 37, 38 Palliative systemic chemotherapy has been thoroughly examined in meta-analyses of prospective clinical trials to achieve superior outcomes in terms of overall survival as opposed to best supportive care among metastatic gastric cancer patients. [7] [8] [9] [10] Palliative gastrectomy as a treatment modality in metastatic gastric cancer has been a subject of considerable attention as several large retrospective series have repeatedly reported the survival benefit it accords patients with metastatic gastric cancer. [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] A systematic analysis and meta-analysis in 2013 found that palliative gastrectomy was associated with improved overall survival among patients with metastatic gastric cancer (HR 0.62; 95% CI, 0.49-0.78; P < 0.001), particularly among those with isolated peritoneal, liver or retroperitoneal lymph node metastasis. 48 These findings, however, were not reproduced in the REGATTA trial, 49 a randomized phase III trial which examined patients with advanced gastric cancer with a single noncurable factor (such as isolated peritoneal, liver or para-aortic lymph node metastasis) treated with systemic chemotherapy alone versus systemic chemotherapy and D1 gastrectomy. One limitation of this trial, however, was that the surgery arm patients did not undergo concomitant metastasectomy. As such, although it may demonstrate that gastrectomy alone may not accord survival benefit above and beyond systemic chemotherapy, it remains unclear if achieving a complete macroscopic resection of the primary cancer and its isolated metastases could potentially prolonged overall survival. A recent systematic review and meta-analysis examining the role of the resection of liver metastases from gastric adenocarcinoma reported significantly improved overall survival (HR 0.50; P < 0.001), particularly among patients with solitary liver metastasis. 50 As such, further prospective controlled trials are needed to investigate if gastrectomy and concomitant metastasectomy accords any survival benefit on top of palliative systemic chemotherapy.
CONCLUSION
Although there remains a significant amount of work left to be done to rigorously assess investigational multimodality treatment approaches to metastatic gastric cancer, it is apparent through our study that metastatic gastric cancer represents a heterogeneous disease, with specific disease complications and treatment outcomes unique to different sites of metastasis. The next frontier in achieving durable survival benefits will require moving past the "one-size-fits-all" paradigm of palliative systemic chemotherapy alone to consider novel multimodality therapies for patient subgroups with isolated metastatic disease and good prognostic factors.
